{"transactions":[{"id":1770501,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":76193,"kind":"organization","name":"SVF Investments (UK) Ltd","position":1,"cik":"0001716729","reported_name":"SVF Investments (UK) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109311,"kind":"organization","name":"SVF Holdings (UK) LLP","position":2,"cik":"0001716727","reported_name":"SVF Holdings (UK) LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109312,"kind":"organization","name":"SoftBank Vision Fund L.P.","position":3,"cik":"0001699940","reported_name":"SoftBank Vision Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15722,"kind":"organization","name":"SB INVESTMENT ADVISERS (UK) LTD","position":4,"cik":"0001731509","reported_name":"SB INVESTMENT ADVISERS (UK) LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2023-10-03T01:00:08.000Z","date":"2023-09-28","kind":"sale","planned":false,"acquired":false,"shares":10000000,"price":12.6,"value":126000000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Securities held of record by SVF Investments (UK) Limited (\"SVF Investments\"). Softbank Vision Fund L.P. is the managing member of SVF Holdings (UK) LLP, which is the sole owner of SVF Investments. SB Investment Advisers (UK) Limited (\"SBIA UK\") has been appointed as the alternative investment fund manager (\"AIFM\") of SoftBank Vision Fund L.P. SBIA UK is authorized and regulated by the UK Financial Conduct Authority and is exclusively responsible for making all decisions related to the acquisition, structuring, financing and disposal of SoftBank Vision Fund L.P.'s investments."}],"balance_after":73031667,"source":{"system":"sec-edgar","filing":"0000950170-23-051247","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1731509/000095017023051247/ownership.xml","form_type":"4"}},{"id":1941745,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":76193,"kind":"organization","name":"SVF Investments (UK) Ltd","position":1,"cik":"0001716729","reported_name":"SVF Investments (UK) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109312,"kind":"organization","name":"SoftBank Vision Fund L.P.","position":2,"cik":"0001699940","reported_name":"SoftBank Vision Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109311,"kind":"organization","name":"SVF Holdings (UK) LLP","position":3,"cik":"0001716727","reported_name":"SVF Holdings (UK) LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15722,"kind":"organization","name":"SB INVESTMENT ADVISERS (UK) LTD","position":4,"cik":"0001731509","reported_name":"SB INVESTMENT ADVISERS (UK) LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2023-03-23T01:00:07.000Z","date":"2023-03-20","kind":"sale","planned":false,"acquired":false,"shares":12000000,"price":8,"value":96000000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Securities held of record by SVF Investments (UK) Limited (\"SVF Investments\"). Softbank Vision Fund L.P. is the managing member of SVF Holdings (UK) LLP, which is the sole owner of SVF Investments. SB Investment Advisers (UK) Limited (\"SBIA UK\") has been appointed as the alternative investment fund manager (\"AIFM\") of SoftBank Vision Fund L.P. SBIA UK is authorized and regulated by the UK Financial Conduct Authority and is exclusively responsible for making all decisions related to the acquisition, structuring, financing and disposal of SoftBank Vision Fund L.P.'s investments."}],"balance_after":83031667,"source":{"system":"sec-edgar","filing":"0000899243-23-009465","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1731509/000089924323009465/doc4.xml","form_type":"4"}},{"id":2116243,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":76193,"kind":"organization","name":"SVF Investments (UK) Ltd","position":1,"cik":"0001716729","reported_name":"SVF Investments (UK) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109312,"kind":"organization","name":"SoftBank Vision Fund L.P.","position":2,"cik":"0001699940","reported_name":"SoftBank Vision Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109311,"kind":"organization","name":"SVF Holdings (UK) LLP","position":3,"cik":"0001716727","reported_name":"SVF Holdings (UK) LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15722,"kind":"organization","name":"SB INVESTMENT ADVISERS (UK) LTD","position":4,"cik":"0001731509","reported_name":"SB INVESTMENT ADVISERS (UK) LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2022-11-16T02:00:10.000Z","date":"2022-11-10","kind":"sale","acquired":false,"shares":4343919,"price":4.75,"value":20633615.25,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Securities held of record by SVF Investments (UK) Limited (\"SVF Investments\"). Softbank Vision Fund L.P. is the managing member of SVF Holdings (UK) LLP, which is the sole owner of SVF Investments. SB Investment Advisers (UK) Limited (\"SBIA UK\") has been appointed as the alternative investment fund manager (\"AIFM\") of SoftBank Vision Fund L.P. SBIA UK is authorized and regulated by the UK Financial Conduct Authority and is exclusively responsible for making all decisions related to the acquisition, structuring, financing and disposal of SoftBank Vision Fund L.P.'s investments."}],"balance_after":95031667,"source":{"system":"sec-edgar","filing":"0000899243-22-035945","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1731509/000089924322035945/doc4.xml","form_type":"4"}},{"id":3484325,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":76193,"kind":"organization","name":"SVF Investments (UK) Ltd","position":1,"cik":"0001716729","reported_name":"SVF Investments (UK) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109312,"kind":"organization","name":"SoftBank Vision Fund L.P.","position":2,"cik":"0001699940","reported_name":"SoftBank Vision Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135094,"kind":"organization","name":"SVF GP (Jersey) Ltd","position":3,"cik":"0001716728","reported_name":"SVF GP (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109311,"kind":"organization","name":"SVF Holdings (UK) LLP","position":4,"cik":"0001716727","reported_name":"SVF Holdings (UK) LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453","published_at":"2019-06-19T18:30:14.000Z","date":"2019-06-19","kind":"purchase","acquired":true,"shares":4957,"price":8.1693,"value":40495.2201,"ownership":{"direct":false,"nature":"See Explanation"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,860,013 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"shares","element":"transactionShares","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"shares","element":"transactionShares","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."},{"field":"shares","element":"transactionShares","label":"F4","text":"The transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Exchange Act, and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $8.00 to $8.27, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (7) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,860,013 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."}],"balance_after":22860013,"source":{"system":"sec-edgar","filing":"0001209191-19-038125","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1716728/000120919119038125/doc4.xml","form_type":"4"}},{"id":3484324,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":76193,"kind":"organization","name":"SVF Investments (UK) Ltd","position":1,"cik":"0001716729","reported_name":"SVF Investments (UK) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109312,"kind":"organization","name":"SoftBank Vision Fund L.P.","position":2,"cik":"0001699940","reported_name":"SoftBank Vision Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135094,"kind":"organization","name":"SVF GP (Jersey) Ltd","position":3,"cik":"0001716728","reported_name":"SVF GP (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109311,"kind":"organization","name":"SVF Holdings (UK) LLP","position":4,"cik":"0001716727","reported_name":"SVF Holdings (UK) LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453","published_at":"2019-06-19T18:30:14.000Z","date":"2019-06-18","kind":"purchase","acquired":true,"shares":6706,"price":8.2107,"value":55060.9542,"ownership":{"direct":false,"nature":"See Explanation"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,860,013 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"shares","element":"transactionShares","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"shares","element":"transactionShares","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."},{"field":"shares","element":"transactionShares","label":"F4","text":"The transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Exchange Act, and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $8.09 to $8.29, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,860,013 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."}],"balance_after":22855056,"source":{"system":"sec-edgar","filing":"0001209191-19-038125","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1716728/000120919119038125/doc4.xml","form_type":"4"}},{"id":3484323,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":76193,"kind":"organization","name":"SVF Investments (UK) Ltd","position":1,"cik":"0001716729","reported_name":"SVF Investments (UK) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109312,"kind":"organization","name":"SoftBank Vision Fund L.P.","position":2,"cik":"0001699940","reported_name":"SoftBank Vision Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135094,"kind":"organization","name":"SVF GP (Jersey) Ltd","position":3,"cik":"0001716728","reported_name":"SVF GP (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109311,"kind":"organization","name":"SVF Holdings (UK) LLP","position":4,"cik":"0001716727","reported_name":"SVF Holdings (UK) LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453","published_at":"2019-06-19T18:30:14.000Z","date":"2019-06-17","kind":"purchase","acquired":true,"shares":6541,"price":8.5346,"value":55824.8186,"ownership":{"direct":false,"nature":"See Explanation"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,860,013 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"shares","element":"transactionShares","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"shares","element":"transactionShares","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."},{"field":"shares","element":"transactionShares","label":"F4","text":"The transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Exchange Act, and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $8.11 to $8.70, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,860,013 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."}],"balance_after":22848350,"source":{"system":"sec-edgar","filing":"0001209191-19-038125","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716728/000120919119038125/doc4.xml","form_type":"4"}},{"id":3489735,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":76193,"kind":"organization","name":"SVF Investments (UK) Ltd","position":1,"cik":"0001716729","reported_name":"SVF Investments (UK) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109312,"kind":"organization","name":"SoftBank Vision Fund L.P.","position":2,"cik":"0001699940","reported_name":"SoftBank Vision Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135094,"kind":"organization","name":"SVF GP (Jersey) Ltd","position":3,"cik":"0001716728","reported_name":"SVF GP (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109311,"kind":"organization","name":"SVF Holdings (UK) LLP","position":4,"cik":"0001716727","reported_name":"SVF Holdings (UK) LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453","published_at":"2019-06-14T18:47:11.000Z","date":"2019-06-14","kind":"purchase","acquired":true,"shares":7144,"price":7.9107,"value":56514.0408,"ownership":{"direct":false,"nature":"See Explanation"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,841,809 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"shares","element":"transactionShares","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"shares","element":"transactionShares","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."},{"field":"shares","element":"transactionShares","label":"F4","text":"The transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Exchange Act, and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.65 to $8.00, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (7) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,841,809 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."}],"balance_after":22841809,"source":{"system":"sec-edgar","filing":"0001209191-19-037284","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1716728/000120919119037284/doc4.xml","form_type":"4"}},{"id":3489734,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":76193,"kind":"organization","name":"SVF Investments (UK) Ltd","position":1,"cik":"0001716729","reported_name":"SVF Investments (UK) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109312,"kind":"organization","name":"SoftBank Vision Fund L.P.","position":2,"cik":"0001699940","reported_name":"SoftBank Vision Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135094,"kind":"organization","name":"SVF GP (Jersey) Ltd","position":3,"cik":"0001716728","reported_name":"SVF GP (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109311,"kind":"organization","name":"SVF Holdings (UK) LLP","position":4,"cik":"0001716727","reported_name":"SVF Holdings (UK) LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453","published_at":"2019-06-14T18:47:11.000Z","date":"2019-06-13","kind":"purchase","acquired":true,"shares":7367,"price":7.9466,"value":58542.6022,"ownership":{"direct":false,"nature":"See Explanation"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,841,809 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"shares","element":"transactionShares","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"shares","element":"transactionShares","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."},{"field":"shares","element":"transactionShares","label":"F4","text":"The transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Exchange Act, and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.67 to $8.39, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,841,809 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."}],"balance_after":22834665,"source":{"system":"sec-edgar","filing":"0001209191-19-037284","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1716728/000120919119037284/doc4.xml","form_type":"4"}},{"id":3489733,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":76193,"kind":"organization","name":"SVF Investments (UK) Ltd","position":1,"cik":"0001716729","reported_name":"SVF Investments (UK) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109312,"kind":"organization","name":"SoftBank Vision Fund L.P.","position":2,"cik":"0001699940","reported_name":"SoftBank Vision Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135094,"kind":"organization","name":"SVF GP (Jersey) Ltd","position":3,"cik":"0001716728","reported_name":"SVF GP (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109311,"kind":"organization","name":"SVF Holdings (UK) LLP","position":4,"cik":"0001716727","reported_name":"SVF Holdings (UK) LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453","published_at":"2019-06-14T18:47:11.000Z","date":"2019-06-12","kind":"purchase","acquired":true,"shares":7500,"price":8.2992,"value":62244.0,"ownership":{"direct":false,"nature":"See Explanation"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,841,809 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"shares","element":"transactionShares","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"shares","element":"transactionShares","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."},{"field":"shares","element":"transactionShares","label":"F4","text":"The transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Exchange Act, and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $8.16 to $8.77, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,841,809 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."}],"balance_after":22827298,"source":{"system":"sec-edgar","filing":"0001209191-19-037284","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716728/000120919119037284/doc4.xml","form_type":"4"}},{"id":3494348,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":76193,"kind":"organization","name":"SVF Investments (UK) Ltd","position":1,"cik":"0001716729","reported_name":"SVF Investments (UK) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109312,"kind":"organization","name":"SoftBank Vision Fund L.P.","position":2,"cik":"0001699940","reported_name":"SoftBank Vision Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135094,"kind":"organization","name":"SVF GP (Jersey) Ltd","position":3,"cik":"0001716728","reported_name":"SVF GP (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109311,"kind":"organization","name":"SVF Holdings (UK) LLP","position":4,"cik":"0001716727","reported_name":"SVF Holdings (UK) LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453","published_at":"2019-06-11T18:46:46.000Z","date":"2019-06-11","kind":"purchase","acquired":true,"shares":7189,"price":8.5817,"value":61693.8413,"ownership":{"direct":false,"nature":"See Explanation"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,819,798 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"shares","element":"transactionShares","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"shares","element":"transactionShares","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."},{"field":"shares","element":"transactionShares","label":"F4","text":"The transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Exchange Act, and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $8.41 to $8.75, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (7) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,819,798 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."}],"balance_after":22819798,"source":{"system":"sec-edgar","filing":"0001209191-19-036230","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1716728/000120919119036230/doc4.xml","form_type":"4"}},{"id":3494347,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":76193,"kind":"organization","name":"SVF Investments (UK) Ltd","position":1,"cik":"0001716729","reported_name":"SVF Investments (UK) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109312,"kind":"organization","name":"SoftBank Vision Fund L.P.","position":2,"cik":"0001699940","reported_name":"SoftBank Vision Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135094,"kind":"organization","name":"SVF GP (Jersey) Ltd","position":3,"cik":"0001716728","reported_name":"SVF GP (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109311,"kind":"organization","name":"SVF Holdings (UK) LLP","position":4,"cik":"0001716727","reported_name":"SVF Holdings (UK) LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453","published_at":"2019-06-11T18:46:46.000Z","date":"2019-06-10","kind":"purchase","acquired":true,"shares":7500,"price":8.3459,"value":62594.25,"ownership":{"direct":false,"nature":"See Explanation"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,819,798 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"shares","element":"transactionShares","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"shares","element":"transactionShares","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."},{"field":"shares","element":"transactionShares","label":"F4","text":"The transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Exchange Act, and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.89 to $8.68, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,819,798 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."}],"balance_after":22812609,"source":{"system":"sec-edgar","filing":"0001209191-19-036230","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1716728/000120919119036230/doc4.xml","form_type":"4"}},{"id":3494346,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":76193,"kind":"organization","name":"SVF Investments (UK) Ltd","position":1,"cik":"0001716729","reported_name":"SVF Investments (UK) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109312,"kind":"organization","name":"SoftBank Vision Fund L.P.","position":2,"cik":"0001699940","reported_name":"SoftBank Vision Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135094,"kind":"organization","name":"SVF GP (Jersey) Ltd","position":3,"cik":"0001716728","reported_name":"SVF GP (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109311,"kind":"organization","name":"SVF Holdings (UK) LLP","position":4,"cik":"0001716727","reported_name":"SVF Holdings (UK) LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453","published_at":"2019-06-11T18:46:46.000Z","date":"2019-06-07","kind":"purchase","acquired":true,"shares":6649,"price":7.965,"value":52959.285,"ownership":{"direct":false,"nature":"See Explanation"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,819,798 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"shares","element":"transactionShares","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"shares","element":"transactionShares","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."},{"field":"shares","element":"transactionShares","label":"F4","text":"The transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Exchange Act, and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.73 to $8.10, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,819,798 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."}],"balance_after":22805109,"source":{"system":"sec-edgar","filing":"0001209191-19-036230","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716728/000120919119036230/doc4.xml","form_type":"4"}},{"id":3499103,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":76193,"kind":"organization","name":"SVF Investments (UK) Ltd","position":1,"cik":"0001716729","reported_name":"SVF Investments (UK) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109312,"kind":"organization","name":"SoftBank Vision Fund L.P.","position":2,"cik":"0001699940","reported_name":"SoftBank Vision Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135094,"kind":"organization","name":"SVF GP (Jersey) Ltd","position":3,"cik":"0001716728","reported_name":"SVF GP (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109311,"kind":"organization","name":"SVF Holdings (UK) LLP","position":4,"cik":"0001716727","reported_name":"SVF Holdings (UK) LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453","published_at":"2019-06-06T19:21:24.000Z","date":"2019-06-06","kind":"purchase","acquired":true,"shares":7082,"price":7.9951,"value":56621.2982,"ownership":{"direct":false,"nature":"See Explanation"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,798,460 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"shares","element":"transactionShares","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"shares","element":"transactionShares","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."},{"field":"shares","element":"transactionShares","label":"F4","text":"The transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Exchange Act, and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.73 to $8.57, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (7) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,798,460 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."}],"balance_after":22798460,"source":{"system":"sec-edgar","filing":"0001209191-19-035293","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1716728/000120919119035293/doc4.xml","form_type":"4"}},{"id":3499102,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":76193,"kind":"organization","name":"SVF Investments (UK) Ltd","position":1,"cik":"0001716729","reported_name":"SVF Investments (UK) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109312,"kind":"organization","name":"SoftBank Vision Fund L.P.","position":2,"cik":"0001699940","reported_name":"SoftBank Vision Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135094,"kind":"organization","name":"SVF GP (Jersey) Ltd","position":3,"cik":"0001716728","reported_name":"SVF GP (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109311,"kind":"organization","name":"SVF Holdings (UK) LLP","position":4,"cik":"0001716727","reported_name":"SVF Holdings (UK) LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453","published_at":"2019-06-06T19:21:24.000Z","date":"2019-06-05","kind":"purchase","acquired":true,"shares":6540,"price":8.015,"value":52418.1,"ownership":{"direct":false,"nature":"See Explanation"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,798,460 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"shares","element":"transactionShares","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"shares","element":"transactionShares","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."},{"field":"shares","element":"transactionShares","label":"F4","text":"The transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Exchange Act, and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.68 to $8.33, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,798,460 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."}],"balance_after":22791378,"source":{"system":"sec-edgar","filing":"0001209191-19-035293","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1716728/000120919119035293/doc4.xml","form_type":"4"}},{"id":3499101,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":76193,"kind":"organization","name":"SVF Investments (UK) Ltd","position":1,"cik":"0001716729","reported_name":"SVF Investments (UK) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109312,"kind":"organization","name":"SoftBank Vision Fund L.P.","position":2,"cik":"0001699940","reported_name":"SoftBank Vision Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135094,"kind":"organization","name":"SVF GP (Jersey) Ltd","position":3,"cik":"0001716728","reported_name":"SVF GP (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109311,"kind":"organization","name":"SVF Holdings (UK) LLP","position":4,"cik":"0001716727","reported_name":"SVF Holdings (UK) LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453","published_at":"2019-06-06T19:21:24.000Z","date":"2019-06-04","kind":"purchase","acquired":true,"shares":7500,"price":7.5881,"value":56910.75,"ownership":{"direct":false,"nature":"See Explanation"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,798,460 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"shares","element":"transactionShares","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"shares","element":"transactionShares","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."},{"field":"shares","element":"transactionShares","label":"F4","text":"The transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Exchange Act, and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.42 to $7.71, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,798,460 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."}],"balance_after":22784838,"source":{"system":"sec-edgar","filing":"0001209191-19-035293","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716728/000120919119035293/doc4.xml","form_type":"4"}},{"id":3499068,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":76193,"kind":"organization","name":"SVF Investments (UK) Ltd","position":1,"cik":"0001716729","reported_name":"SVF Investments (UK) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109312,"kind":"organization","name":"SoftBank Vision Fund L.P.","position":2,"cik":"0001699940","reported_name":"SoftBank Vision Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109311,"kind":"organization","name":"SVF Holdings (UK) LLP","position":3,"cik":"0001716727","reported_name":"SVF Holdings (UK) LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135094,"kind":"organization","name":"SVF GP (Jersey) Ltd","position":4,"cik":"0001716728","reported_name":"SVF GP (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2019-06-06T18:30:59.000Z","date":"2019-06-04","kind":"purchase","acquired":true,"shares":2424242,"price":8.25,"value":19999996.5,"ownership":{"direct":false,"nature":"See Explanation"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Myovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 40,765,599 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"shares","element":"transactionShares","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"shares","element":"transactionShares","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Myovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 40,765,599 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":40765599,"source":{"system":"sec-edgar","filing":"0001209191-19-035256","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716728/000120919119035256/doc4.xml","form_type":"4"}},{"id":3504844,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":76193,"kind":"organization","name":"SVF Investments (UK) Ltd","position":1,"cik":"0001716729","reported_name":"SVF Investments (UK) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109312,"kind":"organization","name":"SoftBank Vision Fund L.P.","position":2,"cik":"0001699940","reported_name":"SoftBank Vision Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135094,"kind":"organization","name":"SVF GP (Jersey) Ltd","position":3,"cik":"0001716728","reported_name":"SVF GP (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109311,"kind":"organization","name":"SVF Holdings (UK) LLP","position":4,"cik":"0001716727","reported_name":"SVF Holdings (UK) LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453","published_at":"2019-06-03T19:18:13.000Z","date":"2019-06-03","kind":"purchase","acquired":true,"shares":5424,"price":7.7092,"value":41814.7008,"ownership":{"direct":false,"nature":"See Explanation"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,777,338 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"shares","element":"transactionShares","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"shares","element":"transactionShares","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."},{"field":"shares","element":"transactionShares","label":"F4","text":"The transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Exchange Act, and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.64 to $7.74, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (8) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,777,338 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."}],"balance_after":22777338,"source":{"system":"sec-edgar","filing":"0001209191-19-034072","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1716728/000120919119034072/doc4.xml","form_type":"4"}},{"id":3504843,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":76193,"kind":"organization","name":"SVF Investments (UK) Ltd","position":1,"cik":"0001716729","reported_name":"SVF Investments (UK) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109312,"kind":"organization","name":"SoftBank Vision Fund L.P.","position":2,"cik":"0001699940","reported_name":"SoftBank Vision Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135094,"kind":"organization","name":"SVF GP (Jersey) Ltd","position":3,"cik":"0001716728","reported_name":"SVF GP (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109311,"kind":"organization","name":"SVF Holdings (UK) LLP","position":4,"cik":"0001716727","reported_name":"SVF Holdings (UK) LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453","published_at":"2019-06-03T19:18:13.000Z","date":"2019-05-31","kind":"purchase","acquired":true,"shares":5071,"price":7.6991,"value":39042.1361,"ownership":{"direct":false,"nature":"See Explanation"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,777,338 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"shares","element":"transactionShares","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"shares","element":"transactionShares","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."},{"field":"shares","element":"transactionShares","label":"F4","text":"The transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Exchange Act, and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.41 to $7.84, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (7) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,777,338 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."}],"balance_after":22771914,"source":{"system":"sec-edgar","filing":"0001209191-19-034072","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1716728/000120919119034072/doc4.xml","form_type":"4"}},{"id":3504842,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":76193,"kind":"organization","name":"SVF Investments (UK) Ltd","position":1,"cik":"0001716729","reported_name":"SVF Investments (UK) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109312,"kind":"organization","name":"SoftBank Vision Fund L.P.","position":2,"cik":"0001699940","reported_name":"SoftBank Vision Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135094,"kind":"organization","name":"SVF GP (Jersey) Ltd","position":3,"cik":"0001716728","reported_name":"SVF GP (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109311,"kind":"organization","name":"SVF Holdings (UK) LLP","position":4,"cik":"0001716727","reported_name":"SVF Holdings (UK) LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453","published_at":"2019-06-03T19:18:13.000Z","date":"2019-05-30","kind":"purchase","acquired":true,"shares":300,"price":8.9066,"value":2671.98,"ownership":{"direct":false,"nature":"See Explanation"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,777,338 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"shares","element":"transactionShares","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"shares","element":"transactionShares","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."},{"field":"shares","element":"transactionShares","label":"F4","text":"The transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Exchange Act, and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $8.71 to $9.03, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,777,338 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."}],"balance_after":22766843,"source":{"system":"sec-edgar","filing":"0001209191-19-034072","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1716728/000120919119034072/doc4.xml","form_type":"4"}},{"id":3504841,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":76193,"kind":"organization","name":"SVF Investments (UK) Ltd","position":1,"cik":"0001716729","reported_name":"SVF Investments (UK) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109312,"kind":"organization","name":"SoftBank Vision Fund L.P.","position":2,"cik":"0001699940","reported_name":"SoftBank Vision Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135094,"kind":"organization","name":"SVF GP (Jersey) Ltd","position":3,"cik":"0001716728","reported_name":"SVF GP (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109311,"kind":"organization","name":"SVF Holdings (UK) LLP","position":4,"cik":"0001716727","reported_name":"SVF Holdings (UK) LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453","published_at":"2019-06-03T19:18:13.000Z","date":"2019-05-30","kind":"purchase","acquired":true,"shares":6951,"price":7.9726,"value":55417.5426,"ownership":{"direct":false,"nature":"See Explanation"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,777,338 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"shares","element":"transactionShares","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"shares","element":"transactionShares","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."},{"field":"shares","element":"transactionShares","label":"F4","text":"The transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Exchange Act, and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.70 to $8.70, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,777,338 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."}],"balance_after":22766543,"source":{"system":"sec-edgar","filing":"0001209191-19-034072","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716728/000120919119034072/doc4.xml","form_type":"4"}},{"id":3508942,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":76193,"kind":"organization","name":"SVF Investments (UK) Ltd","position":1,"cik":"0001716729","reported_name":"SVF Investments (UK) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109312,"kind":"organization","name":"SoftBank Vision Fund L.P.","position":2,"cik":"0001699940","reported_name":"SoftBank Vision Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135094,"kind":"organization","name":"SVF GP (Jersey) Ltd","position":3,"cik":"0001716728","reported_name":"SVF GP (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109311,"kind":"organization","name":"SVF Holdings (UK) LLP","position":4,"cik":"0001716727","reported_name":"SVF Holdings (UK) LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453","published_at":"2019-05-29T20:02:22.000Z","date":"2019-05-29","kind":"purchase","acquired":true,"shares":6882,"price":7.5535,"value":51983.187,"ownership":{"direct":false,"nature":"See Explanation"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,759,592 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"shares","element":"transactionShares","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"shares","element":"transactionShares","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."},{"field":"shares","element":"transactionShares","label":"F4","text":"The transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Exchange Act, and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.40 to $7.69, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (7) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,759,592 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."}],"balance_after":22759592,"source":{"system":"sec-edgar","filing":"0001209191-19-033365","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1716728/000120919119033365/doc4.xml","form_type":"4"}},{"id":3508941,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":76193,"kind":"organization","name":"SVF Investments (UK) Ltd","position":1,"cik":"0001716729","reported_name":"SVF Investments (UK) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109312,"kind":"organization","name":"SoftBank Vision Fund L.P.","position":2,"cik":"0001699940","reported_name":"SoftBank Vision Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135094,"kind":"organization","name":"SVF GP (Jersey) Ltd","position":3,"cik":"0001716728","reported_name":"SVF GP (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109311,"kind":"organization","name":"SVF Holdings (UK) LLP","position":4,"cik":"0001716727","reported_name":"SVF Holdings (UK) LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453","published_at":"2019-05-29T20:02:22.000Z","date":"2019-05-28","kind":"purchase","acquired":true,"shares":3807,"price":7.6818,"value":29244.6126,"ownership":{"direct":false,"nature":"See Explanation"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,759,592 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"shares","element":"transactionShares","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"shares","element":"transactionShares","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."},{"field":"shares","element":"transactionShares","label":"F4","text":"The transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Exchange Act, and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.65 to $7.70, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,759,592 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."}],"balance_after":22732710,"source":{"system":"sec-edgar","filing":"0001209191-19-033365","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1716728/000120919119033365/doc4.xml","form_type":"4"}},{"id":3508940,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":76193,"kind":"organization","name":"SVF Investments (UK) Ltd","position":1,"cik":"0001716729","reported_name":"SVF Investments (UK) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109312,"kind":"organization","name":"SoftBank Vision Fund L.P.","position":2,"cik":"0001699940","reported_name":"SoftBank Vision Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135094,"kind":"organization","name":"SVF GP (Jersey) Ltd","position":3,"cik":"0001716728","reported_name":"SVF GP (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109311,"kind":"organization","name":"SVF Holdings (UK) LLP","position":4,"cik":"0001716727","reported_name":"SVF Holdings (UK) LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453","published_at":"2019-05-29T20:02:22.000Z","date":"2019-05-24","kind":"purchase","acquired":true,"shares":3796,"price":7.7011,"value":29233.3756,"ownership":{"direct":false,"nature":"See Explanation"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,759,592 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"shares","element":"transactionShares","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"shares","element":"transactionShares","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."},{"field":"shares","element":"transactionShares","label":"F4","text":"The transaction was a series of open market purchases made by Roivant under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Exchange Act, and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.66 to $7.74, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,759,592 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or for any other purpose."}],"balance_after":22748903,"source":{"system":"sec-edgar","filing":"0001209191-19-033365","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716728/000120919119033365/doc4.xml","form_type":"4"}},{"id":3513614,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":76193,"kind":"organization","name":"SVF Investments (UK) Ltd","position":1,"cik":"0001716729","reported_name":"SVF Investments (UK) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109312,"kind":"organization","name":"SoftBank Vision Fund L.P.","position":2,"cik":"0001699940","reported_name":"SoftBank Vision Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135094,"kind":"organization","name":"SVF GP (Jersey) Ltd","position":3,"cik":"0001716728","reported_name":"SVF GP (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109311,"kind":"organization","name":"SVF Holdings (UK) LLP","position":4,"cik":"0001716727","reported_name":"SVF Holdings (UK) LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453","published_at":"2019-05-23T20:35:55.000Z","date":"2019-05-23","kind":"purchase","acquired":true,"shares":4802,"price":7.7576,"value":37251.9952,"ownership":{"direct":false,"nature":"See Explanation"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,745,107 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"shares","element":"transactionShares","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"shares","element":"transactionShares","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"shares","element":"transactionShares","label":"F6","text":"The transaction was a series of open market purchases made under a trading plan established pursuant to Rule 10b5-1 under the Exchange Act and in accordance with the safe harbor of Rule 10b-18."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.645 to $7.98, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (8) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,745,107 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":22745107,"source":{"system":"sec-edgar","filing":"0001209191-19-032530","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1716728/000120919119032530/doc4.xml","form_type":"4"}},{"id":3513613,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":76193,"kind":"organization","name":"SVF Investments (UK) Ltd","position":1,"cik":"0001716729","reported_name":"SVF Investments (UK) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109312,"kind":"organization","name":"SoftBank Vision Fund L.P.","position":2,"cik":"0001699940","reported_name":"SoftBank Vision Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135094,"kind":"organization","name":"SVF GP (Jersey) Ltd","position":3,"cik":"0001716728","reported_name":"SVF GP (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109311,"kind":"organization","name":"SVF Holdings (UK) LLP","position":4,"cik":"0001716727","reported_name":"SVF Holdings (UK) LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453","published_at":"2019-05-23T20:35:55.000Z","date":"2019-05-22","kind":"purchase","acquired":true,"shares":5033,"price":8.0584,"value":40557.9272,"ownership":{"direct":false,"nature":"See Explanation"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,745,107 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"shares","element":"transactionShares","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"shares","element":"transactionShares","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"shares","element":"transactionShares","label":"F6","text":"The transaction was a series of open market purchases made under a trading plan established pursuant to Rule 10b5-1 under the Exchange Act and in accordance with the safe harbor of Rule 10b-18."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.825 to $8.43, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (7) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,745,107 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":22740305,"source":{"system":"sec-edgar","filing":"0001209191-19-032530","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1716728/000120919119032530/doc4.xml","form_type":"4"}},{"id":3513612,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":76193,"kind":"organization","name":"SVF Investments (UK) Ltd","position":1,"cik":"0001716729","reported_name":"SVF Investments (UK) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109312,"kind":"organization","name":"SoftBank Vision Fund L.P.","position":2,"cik":"0001699940","reported_name":"SoftBank Vision Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135094,"kind":"organization","name":"SVF GP (Jersey) Ltd","position":3,"cik":"0001716728","reported_name":"SVF GP (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109311,"kind":"organization","name":"SVF Holdings (UK) LLP","position":4,"cik":"0001716727","reported_name":"SVF Holdings (UK) LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453","published_at":"2019-05-23T20:35:55.000Z","date":"2019-05-21","kind":"purchase","acquired":true,"shares":9995,"price":8.5151,"value":85108.4245,"ownership":{"direct":false,"nature":"See Explanation"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,745,107 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"shares","element":"transactionShares","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"shares","element":"transactionShares","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"shares","element":"transactionShares","label":"F4","text":"The transaction was a series of open market purchases made in accordance with the safe harbor of Rule 10b-18 (\"Rule 10b-18\") under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $8.31 to $8.69, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,745,107 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":22735272,"source":{"system":"sec-edgar","filing":"0001209191-19-032530","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716728/000120919119032530/doc4.xml","form_type":"4"}},{"id":3518734,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":76193,"kind":"organization","name":"SVF Investments (UK) Ltd","position":1,"cik":"0001716729","reported_name":"SVF Investments (UK) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109312,"kind":"organization","name":"SoftBank Vision Fund L.P.","position":2,"cik":"0001699940","reported_name":"SoftBank Vision Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135094,"kind":"organization","name":"SVF GP (Jersey) Ltd","position":3,"cik":"0001716728","reported_name":"SVF GP (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109311,"kind":"organization","name":"SVF Holdings (UK) LLP","position":4,"cik":"0001716727","reported_name":"SVF Holdings (UK) LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453","published_at":"2019-05-20T20:35:40.000Z","date":"2019-05-20","kind":"purchase","acquired":true,"shares":1714,"price":8.3867,"value":14374.8038,"ownership":{"direct":false,"nature":"See Explanation"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,725,277 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"shares","element":"transactionShares","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"shares","element":"transactionShares","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"shares","element":"transactionShares","label":"F4","text":"The transaction was a series of open market purchases made in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $8.36 to $8.47, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (8) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,725,277 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":22725277,"source":{"system":"sec-edgar","filing":"0001209191-19-031571","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1716728/000120919119031571/doc4.xml","form_type":"4"}},{"id":3518733,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":76193,"kind":"organization","name":"SVF Investments (UK) Ltd","position":1,"cik":"0001716729","reported_name":"SVF Investments (UK) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109312,"kind":"organization","name":"SoftBank Vision Fund L.P.","position":2,"cik":"0001699940","reported_name":"SoftBank Vision Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135094,"kind":"organization","name":"SVF GP (Jersey) Ltd","position":3,"cik":"0001716728","reported_name":"SVF GP (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109311,"kind":"organization","name":"SVF Holdings (UK) LLP","position":4,"cik":"0001716727","reported_name":"SVF Holdings (UK) LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453","published_at":"2019-05-20T20:35:40.000Z","date":"2019-05-20","kind":"purchase","acquired":true,"shares":8285,"price":7.9833,"value":66141.6405,"ownership":{"direct":false,"nature":"See Explanation"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,725,277 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"shares","element":"transactionShares","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"shares","element":"transactionShares","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"shares","element":"transactionShares","label":"F4","text":"The transaction was a series of open market purchases made in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.35 to $8.35, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (7) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,725,277 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":22723562,"source":{"system":"sec-edgar","filing":"0001209191-19-031571","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1716728/000120919119031571/doc4.xml","form_type":"4"}},{"id":3518732,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":76193,"kind":"organization","name":"SVF Investments (UK) Ltd","position":1,"cik":"0001716729","reported_name":"SVF Investments (UK) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109312,"kind":"organization","name":"SoftBank Vision Fund L.P.","position":2,"cik":"0001699940","reported_name":"SoftBank Vision Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135094,"kind":"organization","name":"SVF GP (Jersey) Ltd","position":3,"cik":"0001716728","reported_name":"SVF GP (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109311,"kind":"organization","name":"SVF Holdings (UK) LLP","position":4,"cik":"0001716727","reported_name":"SVF Holdings (UK) LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453","published_at":"2019-05-20T20:35:40.000Z","date":"2019-05-17","kind":"purchase","acquired":true,"shares":6200,"price":7.3615,"value":45641.3,"ownership":{"direct":false,"nature":"See Explanation"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,725,277 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"shares","element":"transactionShares","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"shares","element":"transactionShares","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"shares","element":"transactionShares","label":"F4","text":"The transaction was a series of open market purchases made in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.03 to $7.85, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,725,277 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":22715277,"source":{"system":"sec-edgar","filing":"0001209191-19-031571","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1716728/000120919119031571/doc4.xml","form_type":"4"}},{"id":3518731,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":76193,"kind":"organization","name":"SVF Investments (UK) Ltd","position":1,"cik":"0001716729","reported_name":"SVF Investments (UK) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109312,"kind":"organization","name":"SoftBank Vision Fund L.P.","position":2,"cik":"0001699940","reported_name":"SoftBank Vision Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135094,"kind":"organization","name":"SVF GP (Jersey) Ltd","position":3,"cik":"0001716728","reported_name":"SVF GP (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109311,"kind":"organization","name":"SVF Holdings (UK) LLP","position":4,"cik":"0001716727","reported_name":"SVF Holdings (UK) LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453","published_at":"2019-05-20T20:35:40.000Z","date":"2019-05-16","kind":"purchase","acquired":true,"shares":5408,"price":6.7896,"value":36718.1568,"ownership":{"direct":false,"nature":"See Explanation"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,725,277 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"shares","element":"transactionShares","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"shares","element":"transactionShares","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"shares","element":"transactionShares","label":"F4","text":"The transaction was a series of open market purchases made in accordance with the safe harbor of Rule 10b-18 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $6.70 to $6.93, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,725,277 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":22709077,"source":{"system":"sec-edgar","filing":"0001209191-19-031571","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716728/000120919119031571/doc4.xml","form_type":"4"}},{"id":3587238,"issuer":{"id":130622,"kind":"organization","name":"Sio Gene Therapies Inc.","symbol":"SIOX"},"owners":[{"id":76193,"kind":"organization","name":"SVF Investments (UK) Ltd","position":1,"cik":"0001716729","reported_name":"SVF Investments (UK) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135094,"kind":"organization","name":"SVF GP (Jersey) Ltd","position":2,"cik":"0001716728","reported_name":"SVF GP (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109312,"kind":"organization","name":"SoftBank Vision Fund L.P.","position":3,"cik":"0001699940","reported_name":"SoftBank Vision Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109311,"kind":"organization","name":"SVF Holdings (UK) LLP","position":4,"cik":"0001716727","reported_name":"SVF Holdings (UK) LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2019-03-19T16:52:30.000Z","date":"2019-03-18","kind":"purchase","acquired":true,"shares":6666667,"price":1.5,"value":10000000.5,"ownership":{"direct":false,"nature":"See Explanation"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Axovant Sciences Ltd. (the\"Issuer\"). Roivant Sciences Ltd. (\"Roivant\") directly holds the 105,952,381 Common Shares reported herein as beneficially owned by the Reporting Persons. Due to certain governance arrangements set forth in Roivant's bylaws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"shares","element":"transactionShares","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"shares","element":"transactionShares","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Axovant Sciences Ltd. (the\"Issuer\"). Roivant Sciences Ltd. (\"Roivant\") directly holds the 105,952,381 Common Shares reported herein as beneficially owned by the Reporting Persons. Due to certain governance arrangements set forth in Roivant's bylaws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":105952381,"source":{"system":"sec-edgar","filing":"0001209191-19-020327","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716728/000120919119020327/doc4.xml","form_type":"4"}},{"id":3723489,"issuer":{"id":130622,"kind":"organization","name":"Sio Gene Therapies Inc.","symbol":"SIOX"},"owners":[{"id":76193,"kind":"organization","name":"SVF Investments (UK) Ltd","position":1,"cik":"0001716729","reported_name":"SVF Investments (UK) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135094,"kind":"organization","name":"SVF GP (Jersey) Ltd","position":2,"cik":"0001716728","reported_name":"SVF GP (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109312,"kind":"organization","name":"SoftBank Vision Fund L.P.","position":3,"cik":"0001699940","reported_name":"SoftBank Vision Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109311,"kind":"organization","name":"SVF Holdings (UK) LLP","position":4,"cik":"0001716727","reported_name":"SVF Holdings (UK) LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2018-12-20T07:06:39.000Z","date":"2018-12-18","kind":"purchase","acquired":true,"shares":10000000,"price":1,"value":10000000.0,"ownership":{"direct":false,"nature":"See Explanation"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Axovant Sciences Ltd. (the\"Issuer\"). Roivant Sciences Ltd. (\"Roivant\") directly holds the 99,285,714 Common Shares reported herein as beneficially owned by the Reporting Persons. Due to certain governance arrangements set forth in Roivant's bylaws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"shares","element":"transactionShares","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general\npartner of SVF Holdings."},{"field":"shares","element":"transactionShares","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Axovant Sciences Ltd. (the\"Issuer\"). Roivant Sciences Ltd. (\"Roivant\") directly holds the 99,285,714 Common Shares reported herein as beneficially owned by the Reporting Persons. Due to certain governance arrangements set forth in Roivant's bylaws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general\npartner of SVF Holdings."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":99285714,"source":{"system":"sec-edgar","filing":"0000899243-18-031456","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716728/000089924318031456/doc4.xml","form_type":"4"}},{"id":3798924,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":76193,"kind":"organization","name":"SVF Investments (UK) Ltd","position":1,"cik":"0001716729","reported_name":"SVF Investments (UK) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109312,"kind":"organization","name":"SoftBank Vision Fund L.P.","position":2,"cik":"0001699940","reported_name":"SoftBank Vision Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135094,"kind":"organization","name":"SVF GP (Jersey) Ltd","position":3,"cik":"0001716728","reported_name":"SVF GP (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109311,"kind":"organization","name":"SVF Holdings (UK) LLP","position":4,"cik":"0001716727","reported_name":"SVF Holdings (UK) LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2018-10-03T17:47:48.000Z","date":"2018-10-01","kind":"purchase","acquired":true,"shares":2678571,"price":14,"value":37499994.0,"ownership":{"direct":false,"nature":"See Explanation"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,703,669 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"shares","element":"transactionShares","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"shares","element":"transactionShares","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Urovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 22,703,669 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":22703669,"source":{"system":"sec-edgar","filing":"0001209191-18-054035","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716728/000120919118054035/doc4.xml","form_type":"4"}},{"id":3901799,"issuer":{"id":130622,"kind":"organization","name":"Sio Gene Therapies Inc.","symbol":"SIOX"},"owners":[{"id":76193,"kind":"organization","name":"SVF Investments (UK) Ltd","position":1,"cik":"0001716729","reported_name":"SVF Investments (UK) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109311,"kind":"organization","name":"SVF Holdings (UK) LLP","position":2,"cik":"0001716727","reported_name":"SVF Holdings (UK) LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135094,"kind":"organization","name":"SVF GP (Jersey) Ltd","position":3,"cik":"0001716728","reported_name":"SVF GP (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109312,"kind":"organization","name":"SoftBank Vision Fund L.P.","position":4,"cik":"0001699940","reported_name":"SoftBank Vision Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2018-06-07T08:24:49.000Z","date":"2018-06-05","kind":"purchase","acquired":true,"shares":14285714,"price":1.75,"value":24999999.5,"ownership":{"direct":false,"nature":"See Explanation"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Axovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 89,285,714 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"shares","element":"transactionShares","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"shares","element":"transactionShares","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Axovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 89,285,714 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":89285714,"source":{"system":"sec-edgar","filing":"0001209191-18-036209","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716728/000120919118036209/doc4.xml","form_type":"4"}},{"id":3970024,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":76193,"kind":"organization","name":"SVF Investments (UK) Ltd","position":1,"cik":"0001716729","reported_name":"SVF Investments (UK) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109312,"kind":"organization","name":"SoftBank Vision Fund L.P.","position":2,"cik":"0001699940","reported_name":"SoftBank Vision Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109311,"kind":"organization","name":"SVF Holdings (UK) LLP","position":3,"cik":"0001716727","reported_name":"SVF Holdings (UK) LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135094,"kind":"organization","name":"SVF GP (Jersey) Ltd","position":4,"cik":"0001716728","reported_name":"SVF GP (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2018-04-04T16:59:56.000Z","date":"2018-04-02","kind":"purchase","acquired":true,"shares":1110015,"price":20.27,"value":22500004.05,"ownership":{"direct":false,"nature":"See Explanation"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Myovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 38,341,357 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"shares","element":"transactionShares","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"shares","element":"transactionShares","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Reporting Persons (as defined below) do not directly own any common shares (the \"Common Shares\") of Myovant Sciences Ltd. (the \"Issuer\"). The Reporting Persons acquired Roivant Sciences Ltd. (\"Roivant\") common shares on September 6, 2017. Roivant directly holds the 38,341,357 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board of Directors (the \"Roivant Board\"), of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\"). SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":38341357,"source":{"system":"sec-edgar","filing":"0001209191-18-023754","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716728/000120919118023754/doc4.xml","form_type":"4"}},{"id":4099452,"issuer":{"id":4953,"kind":"organization","name":"Arbutus Biopharma Corp","symbol":"ABUS"},"owners":[{"id":76193,"kind":"organization","name":"SVF Investments (UK) Ltd","position":1,"cik":"0001716729","reported_name":"SVF Investments (UK) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109312,"kind":"organization","name":"SoftBank Vision Fund L.P.","position":2,"cik":"0001699940","reported_name":"SoftBank Vision Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109311,"kind":"organization","name":"SVF Holdings (UK) LLP","position":3,"cik":"0001716727","reported_name":"SVF Holdings (UK) LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135094,"kind":"organization","name":"SVF GP (Jersey) Ltd","position":4,"cik":"0001716728","reported_name":"SVF GP (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Participating Convertible Preferred Shares","published_at":"2018-01-16T08:56:59.000Z","date":"2018-01-12","kind":"purchase","acquired":true,"shares":664000,"price":100,"value":66400000.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents series A participating convertible preferred shares (the \"Preferred Shares\") purchased by Roivant Sciences Ltd. (\"Roivant\") for $100.00 per Preferred Share (the \"Purchase Price\"), which price is subject to increase to reflect the addition of any unpaid participating cash dividends and unpaid participating in-kind dividends."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the \"Preferred Shares Articles Amendment\"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the \"Common Shares\"), which is determined by dividing (a) the Purchase Price, plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents series A participating convertible preferred shares (the \"Preferred Shares\") purchased by Roivant Sciences Ltd. (\"Roivant\") for $100.00 per Preferred Share (the \"Purchase Price\"), which price is subject to increase to reflect the addition of any unpaid participating cash dividends and unpaid participating in-kind dividends."},{"field":"shares","element":"transactionShares","label":"F2","text":"Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the \"Preferred Shares Articles Amendment\"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the \"Common Shares\"), which is determined by dividing (a) the Purchase Price, plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents series A participating convertible preferred shares (the \"Preferred Shares\") purchased by Roivant Sciences Ltd. (\"Roivant\") for $100.00 per Preferred Share (the \"Purchase Price\"), which price is subject to increase to reflect the addition of any unpaid participating cash dividends and unpaid participating in-kind dividends."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the \"Preferred Shares Articles Amendment\"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the \"Common Shares\"), which is determined by dividing (a) the Purchase Price, plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents series A participating convertible preferred shares (the \"Preferred Shares\") purchased by Roivant Sciences Ltd. (\"Roivant\") for $100.00 per Preferred Share (the \"Purchase Price\"), which price is subject to increase to reflect the addition of any unpaid participating cash dividends and unpaid participating in-kind dividends."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the \"Preferred Shares Articles Amendment\"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the \"Common Shares\"), which is determined by dividing (a) the Purchase Price, plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents series A participating convertible preferred shares (the \"Preferred Shares\") purchased by Roivant Sciences Ltd. (\"Roivant\") for $100.00 per Preferred Share (the \"Purchase Price\"), which price is subject to increase to reflect the addition of any unpaid participating cash dividends and unpaid participating in-kind dividends."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the \"Preferred Shares Articles Amendment\"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the \"Common Shares\"), which is determined by dividing (a) the Purchase Price, plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Represents series A participating convertible preferred shares (the \"Preferred Shares\") purchased by Roivant Sciences Ltd. (\"Roivant\") for $100.00 per Preferred Share (the \"Purchase Price\"), which price is subject to increase to reflect the addition of any unpaid participating cash dividends and unpaid participating in-kind dividends."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the \"Preferred Shares Articles Amendment\"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the \"Common Shares\"), which is determined by dividing (a) the Purchase Price, plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Preferred Shares are directly beneficially owned by Roivant. The Reporting Persons (as defined below) do not directly own any Common Shares of Arbutus Biopharma Corporation (the \"Issuer\") or any Preferred Shares reported herein. The Reporting Persons acquired Roivant common shares on September 6, 2017. Roivant directly holds 16,013,540 Common Shares of the Issuer and the Preferred Shares reported herein. Pursuant to Roivant's internal governance documents, following the appointment to Roivant's board of directors of one or more directors meeting certain independence criteria (each an \"Independent Director\" and collectively the \"Independent Directors\"), dispositions of the Preferred Shares require the approval of a majority of Roivant's board of directors; provided, however, that so long as there is at least one Independent Director as a member of the Roivant Board, of which there are currently two Independent Directors, (continued, see footnote 4)"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(continued from footnote 3) the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant board of directors including disposition of the Preferred Shares directly beneficially owned by Roivant.  As a result, the Reporting Persons may be deemed to have dispositive power over, and to be an indirect beneficial owner of, the Preferred Shares directly beneficially owned by Roivant. The Reporting Persons disclaim beneficial ownership of the Preferred Shares owned by Roivant, except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\").  SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund.  SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\".  SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."}],"balance_after":1164000,"derivative":{"exercise_price":7.13,"expiration_date":"2021-10-16","underlying":"Common shares, no par value","underlying_shares":13025536},"source":{"system":"sec-edgar","filing":"0001209191-18-003511","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716728/000120919118003511/doc4.xml","form_type":"4"}},{"id":4184997,"issuer":{"id":4953,"kind":"organization","name":"Arbutus Biopharma Corp","symbol":"ABUS"},"owners":[{"id":76193,"kind":"organization","name":"SVF Investments (UK) Ltd","position":1,"cik":"0001716729","reported_name":"SVF Investments (UK) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109312,"kind":"organization","name":"SoftBank Vision Fund L.P.","position":2,"cik":"0001699940","reported_name":"SoftBank Vision Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":109311,"kind":"organization","name":"SVF Holdings (UK) LLP","position":3,"cik":"0001716727","reported_name":"SVF Holdings (UK) LLP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135094,"kind":"organization","name":"SVF GP (Jersey) Ltd","position":4,"cik":"0001716728","reported_name":"SVF GP (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Participating Convertible Preferred Shares","published_at":"2017-10-17T09:03:11.000Z","date":"2017-10-16","kind":"purchase","acquired":true,"shares":500000,"price":100,"value":50000000.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents series A participating convertible preferred shares (the \"Preferred Shares\") purchased by Roivant Sciences Ltd. (\"Roivant\") for $100.00 per Preferred Share (the \"Purchase Price\"), which price is subject to increase to reflect the addition of any unpaid participating cash dividends and unpaid participating in-kind dividends."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the \"Preferred Shares Articles Amendment\"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the \"Common Shares\"), which is determined by dividing (a) the Purchase Price, plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents series A participating convertible preferred shares (the \"Preferred Shares\") purchased by Roivant Sciences Ltd. (\"Roivant\") for $100.00 per Preferred Share (the \"Purchase Price\"), which price is subject to increase to reflect the addition of any unpaid participating cash dividends and unpaid participating in-kind dividends."},{"field":"shares","element":"transactionShares","label":"F2","text":"Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the \"Preferred Shares Articles Amendment\"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the \"Common Shares\"), which is determined by dividing (a) the Purchase Price, plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents series A participating convertible preferred shares (the \"Preferred Shares\") purchased by Roivant Sciences Ltd. (\"Roivant\") for $100.00 per Preferred Share (the \"Purchase Price\"), which price is subject to increase to reflect the addition of any unpaid participating cash dividends and unpaid participating in-kind dividends."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the \"Preferred Shares Articles Amendment\"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the \"Common Shares\"), which is determined by dividing (a) the Purchase Price, plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents series A participating convertible preferred shares (the \"Preferred Shares\") purchased by Roivant Sciences Ltd. (\"Roivant\") for $100.00 per Preferred Share (the \"Purchase Price\"), which price is subject to increase to reflect the addition of any unpaid participating cash dividends and unpaid participating in-kind dividends."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the \"Preferred Shares Articles Amendment\"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the \"Common Shares\"), which is determined by dividing (a) the Purchase Price, plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents series A participating convertible preferred shares (the \"Preferred Shares\") purchased by Roivant Sciences Ltd. (\"Roivant\") for $100.00 per Preferred Share (the \"Purchase Price\"), which price is subject to increase to reflect the addition of any unpaid participating cash dividends and unpaid participating in-kind dividends."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the \"Preferred Shares Articles Amendment\"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the \"Common Shares\"), which is determined by dividing (a) the Purchase Price, plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Represents series A participating convertible preferred shares (the \"Preferred Shares\") purchased by Roivant Sciences Ltd. (\"Roivant\") for $100.00 per Preferred Share (the \"Purchase Price\"), which price is subject to increase to reflect the addition of any unpaid participating cash dividends and unpaid participating in-kind dividends."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the \"Preferred Shares Articles Amendment\"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the \"Common Shares\"), which is determined by dividing (a) the Purchase Price, plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Preferred Shares are directly beneficially owned by Roivant. The Reporting Persons (as defined below) do not directly own any Common Shares of Arbutus Biopharma Corporation (the \"Issuer\") or any Preferred Shares reported herein. The Reporting Persons acquired Roivant common shares on September 6, 2017. Roivant directly holds 16,013,540 Common Shares of the Issuer and the Preferred Shares reported herein. Pursuant to Roivant's internal governance documents, following the appointment to Roivant's board of directors of one or more directors meeting certain independence criteria (each an \"Independent Director\" and collectively the \"Independent Directors\"), dispositions of the Preferred Shares require the approval of a majority of Roivant's board of directors; provided, however, that so long as there is at least one Independent Director as a member of the Roivant Board, of which there are currently two Independent Directors, (continued, see footnote 4)"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(continued from footnote 3) the Reporting Persons, voting unanimously with three other major shareholders of Roivant, have the right to override certain decisions of the Roivant board of directors including disposition of the Preferred Shares directly beneficially owned by Roivant.  As a result, the Reporting Persons may be deemed to have dispositive power over, and to be an indirect beneficial owner of, the Preferred Shares directly beneficially owned by Roivant. The Reporting Persons disclaim beneficial ownership of the Preferred Shares owned by Roivant, except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The Roivant common shares are held directly by SVF Investments (UK) Limited (\"SVF Investments\"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP (\"SVF Holdings\"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. (\"SoftBank Vision Fund\").  SVF GP (Jersey) Limited (\"SVF GP\"), is the general partner of SoftBank Vision Fund.  SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the \"Reporting Persons\".  SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings."}],"balance_after":500000,"derivative":{"exercise_price":7.13,"expiration_date":"2021-10-16","underlying":"Common shares, no par value","underlying_shares":9808386},"source":{"system":"sec-edgar","filing":"0001209191-17-057063","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716728/000120919117057063/doc4.xml","form_type":"4"}}]}